The combination of trimethoprim and sulfamethoxazole (TMP/SMX) is widely used as antimicrobial prophylaxis in cancer patients receiving chemotherapy or undergoing haematopoietic stem cell transplantation. In the early 1980s, there was considerable controversy regarding a potential myelotoxic effect of TMP/SMX as reflected in a series of letters to Lancet. [1] [2] [3] In 1995, TMP/SMX prophylaxis was shown to delay neutrophil recovery after bone marrow transplantation in two clinical studies. 4, 5 We now report our preliminary evidence that TMP/SMX prophylaxis may impair the colony growth and engraftment potential of chemotherapy-mobilised autologous peripheral blood stem cells.
Three patients with high-grade non-Hodgkin's lymphoma were treated with a sequential high-dose chemotherapy protocol (Mega-CHOEP) consisting of four cycles of CHOEP (cyclophosphamide, adriamycin, vincristine, etoposide and prednisolone) in escalating doses together with G-CSF. After cycles 1-3, stem cells were harvested to be re-infused after the second, third and fourth chemotherapy course to accelerate haematopoietic recovery. During cycle 1 all patients received 160 mg TMP and 800 mg SMX once a day as antimicrobial prophylaxis. No other medication known to influence stem cell mobilisation or growth was administered.
After cycle 1 all patients showed good stem cell mobilisation and had sufficient leukapheresis harvests (9.4-35 × 10 6 /kg CD34 + stem cells, minimum required 2 × 10 6 /kg CD34 + cells). However, when culturing these cells in a standard methylcellulose assay in the presence of interleukin-3, stem cell factor and GM-CSF we found colony formation to be severely reduced and the minimum of 10 × 10 4 /kg of granulocyte-macrophage colony-forming units (GM-CFU) required for rapid engraftment was not reached in any of the cases. When the same patients received the subsequent chemotherapy courses but this time without TMP/SMX, leukapheresis resulted in good stem cell harvests (3.9-5.5 × 10 6 /kg CD34 + cells) and normal colony formation was found in methycellulose assays (50.0-83.8 × 10 4 /kg GM-CFU). Furthermore, we observed delayed neutrophil recovery after stem cell re-infusion when stem cells mobilised during TMP/SMX prophylaxis were used. The time to reach a neutrophil count Ͻ0.5 × 10 9 /l was 13-14 days after cycle 2 (using stem cells mobilised after cycle 1 with TMP/SMX prophylaxis), compared to 9-11 days after the dose-escalated cycle 4 (using stem cells harvested after cycle 2 without TMP/SMX prophylaxis). In our autologous stem cell transplantation program with over 300 transplants to date, the median time to reach 0.5 × 10 9 /l neutrophils was 10 days. 6 Platelet engraftment was not delayed when compared to our collective patient experience (range 4-42 days) .
To analyse a potential effect of TMP/SMX on stem cell colony formation, we performed methylcellulose cultures with and without TMP/SMX containing pads as used in microbiology for sensitivity testing and designed to release drug amounts comparable to serum levels in vivo. In the cultures containing TMP/SMX we found markedly reduced colony formation particularly in the proximity of the pads (Figures 1 and 2) .
We conclude that antimicrobial prophylaxis with TMP/SMX has a negative effect on mobilised stem cells with reduced colony formation in vitro and delayed neutrophil engraftment in vivo, while the quantity of stem cell as assessed by CD34 + cell counts remains unaffected. We therefore strongly discourage the use of TMP/SMX in the 
